Unfortunately, current HSCT strategies have not proven to be the answer as recent studies have indicated that TP53-mutated MDS patients have dismal outcomes after HSCT [22], although in our limited number of patients who underwent HSCT, survival after HSCT was not different between TP53-mutated and WT patients. This evidence concerns the gene TP53 and myelodysplastic syndrome.